1. Home
  2. SDGR vs SPRY Comparison

SDGR vs SPRY Comparison

Compare SDGR & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$11.55

Market Cap

854.2M

Sector

Health Care

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.25

Market Cap

761.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDGR
SPRY
Founded
1990
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
854.2M
761.6M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
SDGR
SPRY
Price
$11.55
$8.25
Analyst Decision
Buy
Strong Buy
Analyst Count
8
1
Target Price
$21.13
$40.00
AVG Volume (30 Days)
930.7K
1.5M
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
45.14
N/A
EPS
N/A
N/A
Revenue
$255,869,000.00
$84,278,000.00
Revenue This Year
$1.20
$90.76
Revenue Next Year
$4.36
$81.70
P/E Ratio
N/A
N/A
Revenue Growth
23.29
N/A
52 Week Low
$10.95
$6.66
52 Week High
$27.63
$18.63

Technical Indicators

Market Signals
Indicator
SDGR
SPRY
Relative Strength Index (RSI) 42.46 46.94
Support Level $11.11 $6.93
Resistance Level $13.36 $8.70
Average True Range (ATR) 0.49 0.58
MACD 0.02 0.05
Stochastic Oscillator 33.34 57.71

Price Performance

Historical Comparison
SDGR
SPRY

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: